SCHEMBL13115679

SCHEMBL13115679

Cc1ccc(-n2ccc3ncn(CC(=O)O)c3c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 1/20 0.46
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 4/20 0.41
HDAC6 Q9UBN7 1/20 0.41
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 3/20 0.40
HCAR1 Q9BXC0 1/20 0.39
HTT P42858 2/20 0.39
PSMD14 O00487 1/20 0.39
MMP2 P08253 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CSNK2A2 P19784 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13115682 0.86 TSHR (0.57) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4288044 0.79 ADORA2B (0.52) ADORA2BSMN1; SMN2HDAC6LMNACSNK2A2
SCHEMBL18955982 0.78 RAB9A (0.44) ADORA2BMAPTSMN1; SMN2RAB9AMEN1
SCHEMBL3594716 0.74 RXFP1 (0.40) MAPTSMN1; SMN2KMT2APOLBLMNA
SCHEMBL3042764 0.70 PTGS2 (0.48) ADORA2BSMN1; SMN2HDAC6HTTCSNK2A2
SCHEMBL10085099 0.69 HDAC6 (0.61) MAPTSMN1; SMN2NPC1RAB9APOLB
SCHEMBL18956047 0.68 RAB9A (0.60) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL14295057 0.67 ALDH1A1 (0.45) MAPTSMN1; SMN2POLBHDAC6LMNA
SCHEMBL14564402 0.67 NPC1 (0.49) MAPTSMN1; SMN2NPC1RAB9APOLB
SCHEMBL14291770 0.65 PTGS2 (0.49) ADORA2BSMN1; SMN2NPC1HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 ADORA2B 2700/4885MAPT 2809/4885SMN1; SMN2 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.